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OBJECTIVES: Mantle cell lymphoma (MCL) is an aggressive sub-type of non-
 Hodgkin’s lymphoma (NHL) with a poor prognosis. Approximately 6% of incident 
NHL cases are MCL. Following initial treatment, relapsed MCL cases have an 18-
month median survival. In 2008, Health Canada approved bortezomib for relapsed 
MCL patients. Although there is no standard treatment for relapsed MCL, a Canadian 
physician survey indicated FCM (ﬂudarabine, cyclophosphamide, mitoxantrone) was 
a commonly used regimen. Rituximab-containing regimens were excluded as com-
parators because rituximab re-treatment was not uniformly accessible. However, the 
FCM regimen was accessible across Canada. The objective was to evaluate the cost-
effectiveness of bortezomib versus FCM. METHODS: The PINNACLE single-arm 
study evaluated bortezomib in relapsed MCL patients. Most of these patients had 
received rituximab previously, and therefore provided rationale to support using a 
non-rituximab regimen as a comparator. Published literature identiﬁed one relevant 
FCM study. A ﬁve-year time horizon was selected as most patients were at this point 
deceased. Costs and beneﬁts were discounted by 5% and a provincial Ministry of 
Health perspective was taken. The overall survival for bortezomib was projected 
based on the PINNACLE study. Health utilities were obtained from a published study 
on aggressive NHL. Resource use included costs of drugs, intravenous administration 
and managing key adverse events. The survival of relapsed MCL patients treated with 
standard chemotherapy, including ﬂudarabine regimens, was validated from a cohort 
of patients from the British Columbia Cancer Agency. This ensured the FCM data in 
the analysis was not an underestimation of actual practice results. RESULTS: The 
discounted QALYs were 1.47 (Bortezomib) and 0.86 (FCM). The total cost was 
CAN $27,886 (bortezomib) and $5,059 (FCM). The ICER was $37,253 per QALY. 
Results were most sensitive to the amount of bortezomib used and the survival of 
these patients. CONCLUSIONS: Bortezomib is an approved and cost-effective option 
in these difﬁcult to treat patients.
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OBJECTIVES: To estimate the incremental cost-effectiveness of bortezomib (BTZ) 
compared with lenalidomide plus dexamethasone (LENDEX) and dexamethasone 
(DEX) for the treatment of relapsed/refractory multiple myeloma in the Nordic coun-
tries. METHODS: The model was based on a ‘partitioned survival analysis’ that 
allows survival data to be decomposed into three states 1) alive before disease progres-
sion; 2) alive after progression; and 3) dead. The effects of treatment on time to pro-
gression and overall survival (OS) were obtained from published reports of the APEX, 
MM-009 and MM-010 randomized clinical trials. OS hazard ratios were estimated 
using a mixed-treatment-comparison meta analysis. Costs were estimated using pub-
lished local sources and local Delphi panels, and include drug and administration, 
adverse events and relapses, and end-of-life costs. Utility estimates are derived from 
the literature. The robustness was evaluated by 1-way and probabilistic sensitivity 
analysis. RESULTS: BTZ mean OS is 38.6 months compared to 24.5 and 37.8 months 
for DEX and LENDEX respectively. Mean lifetime direct medical costs for BTZ are 
ranging from a98,408 (Sweden) to a194,656 (Denmark). For Finland, Norway and 
Sweden mean incremental cost per LYG of BTZ compared to DEX is between a42,145 
and a46,749. The corresponding cost per QALY is between a54,451 and a60,564. 
Denmark has higher values of a62,748 and a81,560 respectively. BTZ is dominant 
compared to LENDEX in all countries. For the BTZ DEX comparison, the model is 
most sensitive to changes in utilities prior to relapse, BTZ costs and number of 
administrations. CONCLUSIONS: BTZ and LENDEX are projected to prolong 
survival relative to DEX. Finland, Norway and Sweden show very similar cost-
 effectiveness results. Denmark has higher ICERs because of higher cost of care in 2nd 
and 3rd line implying a relative disadvantage for drugs prolonging life. From a Nordic 
perspective, BTZ is cost-effective compared to DEX and dominant compared to 
LENDEX.
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OBJECTIVES: New treatment options for advanced non-squamous NSCLC offer 
improved survival over standard chemotherapy but must also offer value for money. 
Bevacizumab, a humanised monoclonal antibody against VEGF, plus chemotherapy 
increases overall survival and progression-free-survival (PFS) in advanced NSCLC 
patients versus chemotherapy alone. Pemetrexed, a thymidylate synthase inhibitor, has 
shown non-inferiority over cisplatin plus gemcitabine. This study evaluated the cost-
effectiveness of BCG compared with iPC in Germany. METHODS: A Markov model 
evaluated the average costs and beneﬁts of treating advanced or recurrent NSCLC 
patients with BCG or PC. The patient characteristics of an average German hospital 
patient were applied. The model assumes patients move from pre-progressive to pro-
gressed disease to death, according to a set of transition probabilities derived from 
the respective pivotal trials and appropriate indirect comparison methodology. Drug 
costs assume underlying chemotherapy is given for up to 6 cycles, but that bevaci-
zumab is administered until progression or unacceptable toxicity. The model estimates 
average survival, PFS, drug, administration and progression costs per patient treated 
with BCG or PC and the incremental cost-effectiveness ratio. RESULTS: BCG gave 
mean survival of 1.51 versus 1.31 years with PC and mean PFS of 0.75 versus 0.54 
years, respectively. The mean total monthly treatment costs for the base case analysis 
were a5870 versus a6637, respectively (savings of a767 for BCG per patient). Monthly 
drug costs alone were a5497 for BCG compared with a6161 with PC. CONCLU-
SIONS: BCG triplet-therapy offers greater clinical beneﬁts than PC doublet-therapy 
at a lower overall cost, suggesting that BCG is dominating PC in treating patients with 
advanced NSCLC in Germany. The overall cost of BCG is likely to further reduce 
following the recent gemcitabine patent expiry, providing potential further cost 
savings of BCG to the German health care system.
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OBJECTIVES: To evaluate the costs and clinical outcomes of rituximab (R) added to 
ﬁrst line chemotherapy vs. chemotherapy in patients with chronic lymphocytic leuke-
mia (CLL) in Poland. METHODS: A three health state transition model was developed 
to evaluate the cost-effectiveness of treating patients with either chemotherapy 
(ﬂudarabine cyclophosphamide; FC) or R  FC. Patient level data were obtained 
from the pivotal study CLL-8 (Hallek et al., 2008). As chlorambucil (C) is frequently 
used in Poland, an indirect comparison of R-FC vs. C was included (patient data were 
obtained from the CLL-4 study, Catovsky et al. 2007). Patients commenced in the 
progression-free (PFS) state with transitions to progressive disease or death. PFS and 
overall survival (OS) data were extrapolated over 15 years with monthly cycles. Utility 
values originated from Hancock et. al., 2002 study. The perspective was the Public 
Payer. Direct costs were obtained from 4 reference oncology centers and derived from 
the National Health Fund. Effects and costs (PLN) were discounted at 3.5% and 5% 
p.a. respectively (Polish HTA guidelines). RESULTS: R-FC was more effective than 
FC or C. R-FC treatment resulted in 0.92 life years gained (LYG) and 0.79 quality–
adjusted life years (QALY) vs. FC. Total mean costs per patient were higher for R-FC 
vs. FC, however the incremental cost-effectiveness ratios (ICERs) were 70,145 PLN/
LYG and 81,730 PLN/QALY. The LYG and QALY gains for R-FC vs. chlorambucil 
were 1.87 and 1.63 leading to ICERs of 47,007 PLN/LYG and 53,826 PLN/QALY, 
respectively. Results were most sensitive to discounting rates changes and the time 
horizon. Nevertheless, in all scenarios R-FC treatment remained cost-effective. CON-
CLUSIONS: R-FC substantially improves patients outcomes and is an economically 
effective 1st line treatment for CLL patients when compared to FC or chlorambucil.
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OBJECTIVES: New treatment options for advanced NSCLC can offer improved sur-
vival over standard chemotherapy but should also offer value for money. Bevaci-
zumab, a humanised monoclonal antibody (MAb) against VEGF, plus chemotherapy 
increases overall survival and progression-free-survival in patients with advanced 
NSCLC versus chemotherapy alone. Cetuximab, a MAb targeting EGFR, plus chemo-
therapy also improved outcomes in these patients. This study compared the costs and 
outcomes associated with treating patients with BCG or CVC in Spain. METHODS: 
A Markov model was used to compare costs and outcomes associated with treating 
patients with advanced or recurrent NSCLC with BCG or CVC. The model assumes 
patients move from pre-progressive to progressed disease then to death, according to 
a set of transition probabilities derived from an indirect comparison (IC) of the efﬁcacy 
of BCG and CVC in terms of progression-free survival (PFS) using data from the 
respective pivotal trials and appropriate IC methodology. Cost data were derived from 
local sources. Drug costs assumed chemotherapy was given for up to 6 cycles, cetux-
imab was administered at an initial dose of 400 mg/m2 (then 250 mg/m2 weekly) until 
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progression and bevacizumab 7.5 mg/kg was administered until progression. The 
model estimated average survival, PFS, drug and administration costs and total costs 
per patient treated with BCG or CVC. RESULTS: BCG treatment results in a mean 
survival of 1.51 years versus 1.38 years with CVC. Both drug and administration costs 
were lower with BCG than CVC and the mean total cost per patient treated with BCG 
was less costly than CVC (a33,153 versus a40,700, respectively). CONCLUSIONS: 
BCG, compared with CVC, gives a greater clinical beneﬁt and is less costly. Therefore, 
BCG is dominant over CVC and should be considered to be therapy of choice for 
treating patients with advanced NSCLC.
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OBJECTIVES: Implemented in several countries, biennial Guaiac Fecal Occult Blood 
Test (FOBT) is used as mass screening for Colorectal Cancer. Using Guaiac FOBT as 
the reference strategy, we estimated the cost-effectiveness of three screening alterna-
tives: biennial Immunological FOBT, Computed Tomography Colonoscopy every 5     
and 10 years (respectively CTC-5 and CTC-10). METHODS: Over a 30-year horizon 
and from the perspective of a third-party payer, we developed a partially observed 
Markov model on a hypothetical cohort of 100,000 subjects at average risk for 
colorectal cancer. Costs were based on French data. Epidemiological parameters were 
from the international literature. The incremental net beneﬁt framework was used to 
describe our results. Then, we performed univariate and probabilistic sensitivity analy-
ses. RESULTS: Compared with Guaiac test strategy, each alternative led to an increase         
in both discounted costs and life-years gained (LYG). The optimal strategy was       
 function of the willingness to pay (WTP). Immunological FOBT resulted in lower   
prevention rate (14%) than CTC-5 (38%) or CTC-10 (24%). However, the two-year 
frequency of Immunological FOBT enabled an earlier detection of cancers conducing 
to higher number of LYG than CTC-10. Outcomes were sensitive to adherence rates.       
Probabilistic sensibility analysis suggested that below a WTP of 1,807a/LYG, the refer-
ence strategy was optimal whilst CTC-10 was preferred between a1807 and a8124 /
LYG. Beyond a WTP of a8124/LYG, CTC-5 provided the highest incremental net 
beneﬁt. Although, Immunological FOBT was subject to extended dominance, it was 
still optimal for one third of the simulations for a WTP between a15,000 and 
a120,000/LYG. This result was due to close expected net beneﬁts between Immuno-
logical FOBT and CTC-5 and induced uncertainty in the choice of the optimal strat-
egy. CONCLUSIONS: From a reasonable willingness to pay of the third-party payer, 
Guaiac FOBT strategy was no longer optimal for colorectal cancer mass screening.
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OBJECTIVES: An economic model was constructed to assess the cost effectiveness of           
docetaxel/cyclophosphamide (TC) compared with doxorubicin/cyclophosphamide 
(AC) as adjuvant treatment for women with operable breast cancer. An Australian 
government perspective was adopted for the analysis. METHODS: A cost utility   
analysis was undertaken for a model population of women with operable breast 
cancer. The median age at baseline was 51 years. Four cycles of docetaxel (75 mg/m 2) 
plus cyclophosphamide (600 mg/m 2) were compared to four cycles of doxorubicin 
(60 mg/m 2) plus cyclophosphamide (600 mg/m 2). Seven year overall survival and 
disease free survival results were utilised from a pivotal randomised control trial (Jones 
et al, 2009). Overall survival was extrapolated to a 35 year model horizon. Utility 
weights were derived from a valuation study conducted in an Australian general 
population sample. Expert opinion garnered from a treatment practice survey of 
clinicians informed the average frequency and type of resources required for diagnosis 
and treatment of recurrence of disease. RESULTS: Adjuvant treatment of operable    
breast cancer with TC was associated with incremental costs of A$6253, and 
incremental QALYs (Quality Adjusted Life Years) of 0.48 (at 35 years) when compared 
to AC. The incremental cost–effectiveness ratio was estimated at approximately 
A$13,000 per QALY when assessed at 35 years. CONCLUSIONS: We found TC to    
be a highly cost effective intervention as adjuvant treatment of operable breast cancer 
when compared with AC in the Australian setting.
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OBJECTIVES: To develop a cost-effectiveness analysis to compare docetaxel vs 
docetaxeltrastuzumab as ﬁrst line therapy in the treatment of patients with advanced 
or metastatic breast cancer HERneu from the public health system Perspective in 
Mexico. METHODS: A markov model was built in order to simulate the clinic course 
of a cohort of patients with metastatic breast cancer HERneu in treatment with 
docetaxel vs docetaxeltrastuzumab as ﬁrst line treatment. The model include 
three health states (without progression, progression and death), with a 12- month 
following. Conceptual frame and clinical course was based on literature review and 
controlled clinical trials. In order to deﬁne resources and procedures to set costs, a 
literature search for economic evaluation and different disease management alterna-
tives was done. The drugs costs were obtained from the costs of purchasing published 
by the Mexican Institute of Social Security and included diagnosis, treatment, follow-
ing and medical support. The clinical beneﬁt of the treatment is to be determined by 
Progression-Free Survival (PFS). RESULTS: Using docetaxeltrastuzumab 49.1% of 
patients were free of progression and 25.6% of those who used only docetaxel during 
the 12 months of management; In other words, to maintain a patient free of progres-
sion at 12 moths is necessary to treat 2.04 and 3.91 patients with docetaxeltrastuzumab 
and docetaxel respectively. The expected cost with docetaxeltrastuzumab is 
US$32,460.87 and with docetaxel US$22,735.74. The cost to maintain a patient free 
of progression at 12 moths is US$66,085.92 and US$88,899.50 (mean cost effective-
ness ratio) and the ICER is US$41,305. CONCLUSIONS: Results show that 
docetaxeltrastuzumab is a cost effective therapy when comparing with docetaxel in 
ﬁrst line therapy for patients with metastatic breast cancer.
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OBJECTIVES: Because of an unfavorable health economics assessment commissioned 
by the Ministry of Health, in Austria HPV vaccination costs are not covered by the 
government. We have performed an additional assessment based on essentially the 
same cost data and only slightly different assumptions concerning infection and disease 
propagation but simulating cohorts for their whole life expectancy. METHODS: The 
applied model is of a hybrid type. The dynamic infection model was formulated as a 
SIR model with delayed transition from the recovered state into the susceptible state. 
It was validated by comparison with empirical infection rates for the different HPV 
strains within age groups. Vaccination of 85% of 12 year old girls was modeled. Two 
equally sized cohorts of girls were followed from birth to 100 years of life, one vacci-
nated against HPV types 16 and 18 and one unvaccinated, both were assumed to have 
unchanged opportunistic screening. All estimates were based on 1000 runs of these 
cohorts. The infection model was validated by comparison of the unvaccinated cohort 
with the Austrian incidence and mortality data for the years 2002 to 2007. RESULTS: 
Vaccination of 85% of 12 year old girls resulted in a decrease of mortality by 64% and 
incidence by 69%. Cervical intraepithelial neoplasias (CIN) were reduced too: 27%, 
46% and 49% for CIN1 to CIN3, respectively. Without discounting vaccination was 
cost saving. Assuming discount rates between 2 and 6% the incremental cost-effective-
ness ratio (ICER) was 6,000.- to 21,000.- a/LYG. Sensitivity analyses demonstrate that, 
except for discount rates, a booster vaccination and no cross-protection against 
non-vaccine types has the greatest inﬂuence on ICER. CONCLUSIONS: Also for the 
Austrian health care system vaccination is cost-effective in the long run, although it’s 
full economic impact is—concerning cervical cancer—seen only after decades.
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OBJECTIVES: To estimate the cost-effectiveness of docetaxel for breast cancer treat-
ment in adjuvant and metastatic settings. Three comparisons are performed: 3 cycles 
of ﬂuorouracil, epirubicin and cyclosphophamide followed for 3 cycles of docetaxel 
(3FEC100-3D) versus 6 cycles of ﬂuorouracil, epirubicin and cyclosphophamide 
(6FEC100); 6 cycles of ﬂuorouracil, doxorubicin and cyclosphophamide (FAC) versus 
6 cycles of docetaxel, doxorubicin and cyclosphophamide (TAC), both as adjuvant 
treatments; and docetaxel versus paclitaxel in metastatic breast cancer (MBC). 
METHODS: The lifetime Markov model used for the adjuvant setting analysis, 
developed by Aremis Consultants, considers 6-month cycles and 4 health states: no 
recurrence; loco-regional recurrence; metastatic recurrence; and death. The model for 
MBC, created by United Bio Source, lasts for 10 years with 3-week cycles and 3 health 
states: no progression; progression; and death. Transition probabilities were derived 
from head-to-head clinical trials. Direct medical costs were estimated for the Society 
and the tertiary cancer centre Instituto Português de Oncologia de Lisboa (IPOL) 
perspectives. Resource consumption was based on clinical practice at IPOL (patient-
level data). Unit costs were derived from ofﬁcial sources and IPOL data. RESULTS: 
The projected survival advantage was 0.93 years for TAC compared to FAC, with an 
incremental cost of a8369 for the Society and a8031 for IPOL, and 0.49 years for 
3FEC100-3D compared to 6FEC100, with incremental costs below a3700 for either 
perspective. In both cases, incremental costs per life year gained (ICER) are below 
a9000. In MBC, the predicted incremental life expectancy with Docetaxel is 6 months, 
being the incremental cost of around a11,000 for either Society or IPOL. The ICER 
is a21,905 and a22,329, respectively. Sensitivity analysis shows that these ﬁndings are 
only responsive to changes in the relative clinical gains of docetaxel. CONCLUSIONS: 
